Moreover, adenoviral delivery of S100A1 was effective in the treatment of heart failure in small and large animals and improving the failing function of animal and human cardiomyocytes, clearly positions S100A1 as an appropriate target for cardiac gene therapy [36] [S28, S29]. The gene discussed is S100A1; the disease is heart failure.